Page 997 - Read Online

Page 18 of 18 Machado. Hepatoma Res 2020;6:84 I http://dx.doi.org/10.20517/2394-5079.2020.90

144. Bakhshipour A, Kaykhaei MA, Moulaei N, Mashhadi MA. Prevalence of coeliac disease in patients with non-alcoholic fatty liver disease.
Arab J Gastroenterol 2013;14:113-5.
145. Rahimi AR, Daryani NE, Ghofrani H, et al. The prevalence of celiac disease among patients with non-alcoholic fatty liver disease in Iran.
Turk J Gastroenterol 2011;22:300-4.
146. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory
bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003;36:417-20.
147. Tovoli F, Negrini G, Fari R, et al. Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet:
beyond traditional metabolic factors. Aliment Pharmacol Ther 2018;48:538-46.
148. Reilly NR, Lebwohl B, Hultcrantz R, Green PH, Ludvigsson JF. Increased risk of non-alcoholic fatty liver disease after diagnosis of
celiac disease. J Hepatol 2015;62:1405-11.
149. Abenavoli L, Milic N, De Lorenzo A, Luzza F. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease.
Endocrine 2013;43:65-7.
150. van Zutphen T, Ciapaite J, Bloks VW, et al. Malnutrition-associated liver steatosis and ATP depletion is caused by peroxisomal and
mitochondrial dysfunction. J Hepatol 2016;65:1198-208.
151. Machado MV, Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. Ann Hepatol 2009;8 Suppl 1:S67-75.
152. HH AK. Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Rev Gastroenterol Hepatol
2017;11:911-24.
153. Reynolds TM, Mewies C, Hamilton J, Wierzbicki AS, group PPC. Identification of rare diseases by screening a population selected on
the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. J Clin
Pathol 2018;71:608-13.
154. Khoury J, Zohar Y, Shehadeh N, Saadi T. Glycogenic hepatopathy. Hepatobiliary Pancreat Dis Int 2018;17:113-8.
155. Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease. Curr Opin Lipidol 2020;31:49-55.
156. Noto D, Arca M, Tarugi P, Cefalu AB, Barbagallo CM, Averna MR. Association between familial hypobetalipoproteinemia and the risk of
diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature. Acta Diabetol 2017;54:111-22.
157. Pelusi S, Baselli G, Pietrelli A, et al. Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease.
Sci Rep 2019;9:3682.
158. Dela Cruz ACD, Bugianesi E, George J, et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver
disease: international follow up study. Gastroenterology 2014;146:A379.
159. Shao C, Ye J, Li F, Feng S, Wang W, Zhong B. Different predictors of steatosis and fibrosis severity among lean, overweight and obese
patients with nonalcoholic fatty liver disease. Dig Liver Dis 2019;51:1392-9.
160. Hagstrom H, Nasr P, Ekstedt M, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a
long-term follow-up study. Hepatol Commun 2018;2:48-57.
161. Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AK. Clinical, anthropometric, biochemical, and histological characteristics
of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol 2014;33:452-7.
162. Denkmayr L, Feldman A, Stechemesser L, et al. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype
similar to obese patients. J Clin Med 2018;7.
163. Akyuz U, Yesil A, Yilmaz Y. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin
levels. Scand J Gastroenterol 2015;50:341-6.
164. Yilmaz Y, Senates E, Ayyildiz T, et al. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome. Eur J
Clin Invest 2012;42:411-8.
165. Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-
overweight individuals. Liver Int 2016;36:275-83.
166. Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically
abnormal and have a higher risk for mortality. Clin Diabetes 2019;37:65-72.
167. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-
EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402.
168. Alam S, Jahid Hasan M, Khan MAS, Alam M, Hasan N. Effect of weight reduction on histological activity and fibrosis of lean
nonalcoholic steatohepatitis patient. J Transl Int Med 2019;7:106-14.
169. Albu JB, Heilbronn LK, Kelley DE, et al. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2
diabetes. Diabetes 2010;59:627-33.
170. Ohkawara K, Tanaka S, Miyachi M, Ishikawa-Takata K, Tabata I. A dose-response relation between aerobic exercise and visceral fat
reduction: systematic review of clinical trials. Int J Obes (Lond) 2007;31:1786-97.
171. Ismail I, Keating SE, Baker MK, Johnson NA. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise
training on visceral fat. Obes Rev 2012;13:68-91.